Literature DB >> 27524921

Ischemic retinopathy associated with Crohn's disease.

Rubens Camargo Siqueira1, Roberto Luiz Kaiser Junior2, Lilian Piron Ruiz2, Milton Arthur Ruiz2.   

Abstract

PURPOSE: To report a case of a patient with ischemic retinopathy associated with Crohn's disease. CASE REPORT: This report presents a case of a 28-year-old female patient with Crohn's disease and sudden decrease of visual acuity in the right eye. Fluorescein angiography, optical coherence tomography, and multifocal electroretinography confirmed the clinical features of ischemic retinopathy. After systemic corticosteroid treatment, the patient developed epiretinal membrane without significant improvement in visual acuity. DISCUSSION: The patient presented with ischemic retinopathy associated with Crohn's disease with deficiency of central visual acuity. Periodic examination by a retina specialist is recommended for patients being treated for Crohn's disease.

Entities:  

Keywords:  Crohn; ERG; OCT; epiretinal membrane; ischemic retinopathy

Year:  2016        PMID: 27524921      PMCID: PMC4966643          DOI: 10.2147/IMCRJ.S108855

Source DB:  PubMed          Journal:  Int Med Case Rep J        ISSN: 1179-142X


Introduction

Crohn’s disease (CD) is a regional enteritis that affects the terminal ileum, but has the potential of involving any segment of the gastrointestinal tract of the patient. The etiology of CD is unknown, but several proven risk factors exist such as family history, smoking, oral contraceptives, diet, and ethnicity. The combination of risk factors, and aberrant autoimmune response in the intestinal mucosa with endothelial dysfunction lead to digestive tract malfunctioning. The current treatment is not ideal. Therapy generally involves steroids and antitumor necrosis factor alpha blockers but about one-third of patients fail to respond (primary nonresponders) and 10% of patients do not tolerate or are primary nonresponders to all drugs used. One-third of responders to antitumor necrosis factor treatment show transient loss of response (secondary nonresponders). Severe cases may require partial resection of a segment of bowel, possibly total colectomy with the placement of stoma bags for feces when the disease affects the rectum. Ophthalmic manifestations have been reported to occur in up to 12% of patients with CD and most of them include iritis, uveitis, episcleritis, and conjunctivitis. However, posterior segment manifestations are very rare, occurring in less than 1% of patients.1–4

Case report

A 28-year-old female was admitted because of sudden decrease of visual acuity in the right eye. She had been diagnosed as suffering from CD. She had undergone resection of a 40 cm segment of bowel due to stenosis. She was refractory to treatment using corticosteroids, azathioprine, infliximab, and adalimumab. The patient suffered repeated episodes of abdominal pain, mucous bloody diarrhea, weight loss, and depression. At presentation, she underwent a complete ophthalmological examination. Visual acuity was 20/400 in the right eye. Examination of the anterior segment was normal and the lens was clear. Bilateral intraocular pressure was 13 mmHg. Ophthalmoscopic examination with mydriasis showed severe ischemic retinopathy in the right eye (Figure 1A). Retinal fluorescein angiography showed ischemic retinopathy, especially involving the macular area (Figure 1B). Optical coherence tomography showed thickening and hyperreflectivity of the inner retinal layers, including the nerve fiber and ganglion cell layers owing to ischemia of the superficial capillary plexus (Figure 1C) and multifocal electroretinography showed a decrease of electrical responses representing central macula (Figure 1D).
Figure 1

Evaluation of anatomical and functional status before and after treatment using FA, OCT, and ERG.

Notes: (A) Ischemic retinopathy with alteration of foveal reflex (arrow) in the right eye. (B) Retinal FA showing ischemic retinopathy, especially involving the macular area (arrow). (C) OCT showed thickening and hyperreflectivity of the inner retinal layers (arrow). (D) Multifocal ERG showed a decrease in electrical responses from central macula (arrow). (E) Resolution of cotton wool spots (arrow). (F) Reperfusion of some previously ischemic areas during examination with fluorescein (arrow). (G) OCT showed formation of epiretinal membrane (arrow). (H) Multifocal ERG remained at low amplitudes corresponding to central area (arrow), indicating macular dysfunction.

Abbreviations: Amp, amplitude; ERG, electroretinography; FA, fluorescein angiography; N/I, inferior nasal; N/S, superior nasal; OCT, optical coherence tomography; P1, peak amplitude response; T/I, inferior temporal; T/S, superior temporal.

These features suggested the clinical diagnosis of ischemic retinopathy secondary to CD. We prescribed prednisone 60 mg daily and scheduled new follow-up tests. Visual acuity showed a slight improvement (20/150), with resolution of cotton wool spots (Figure 1E) and reperfusion of some previously ischemic areas during examination with fluorescein (Figure 1F). After 3 months, we observed the formation of an epiretinal membrane (Figure 1G), but without significant macular edema or bleeding. Multifocal electroretinography remained at low amplitudes meaning macular dysfunction (Figure 1H).

Discussion

We present a case of CD complicated by ischemic retinopathy with irreversible damage of central visual acuity. Several factors are associated with an increased risk of ocular manifestations. Patients with colitis and ileocolitis tend to have a higher risk of ocular involvement compared to those with ileitis alone.5 Presence of other organ involvement also increases the risk.5,6 Particularly, in patients with CD and arthralgia, the risk of ocular involvement increases to 33%.6 Falavarjani et al7 described a 9-year-old male with biopsy-proven CD who developed a cilioretinal artery-sparing central retinal artery occlusion. Trojet et al8 reported a 55-year-old male with CD with associated retinal vasculitis involving the veins, papillitis, cystoid macular edema. The pathophysiology of the extraintestinal manifestations of CD is not well understood, but it is most likely mediated by the inflammatory nature of the disease. Several proposed mechanisms include circulating antigen–antibody complexes or autoantibody production against cellular antigens shared by the colon and extraintestinal organs.9 Inflammation causing damage to mucosa of the intestinal epithelium may allow proteins or microorganisms to pass through the intestinal barrier and cause a reactive lymphoid tissue response. This, in turn, results in antibody production or antigen–antibody complexes that circulate in the body and cause systemic inflammation. This immune response to a colonic antigen may explain why ocular manifestations may occur more commonly with colitis and ileocolitis than with small bowel involvement alone. Microbial pathogens, through molecular mimicry, may also contribute to the pathogenesis, though this is still being investigated. Genetic factors may also play a role in ocular manifestations. Patients with extraintestinal manifestations of CD have a higher prevalence of HLA-B27 type leukocytes than the regular.10 Ocular complications are categorized as primary, secondary, and coincidental.11 Primary complications are temporally associated with CD exacerbations and tend to resolve with systemic treatment of the intestinal inflammation. These include keratopathy, episcleritis, and scleritis. Secondary complications arise from primary complications. Examples include cataract formation due to treatment with corticosteroids, scleromalacia due to scleritis, and dry eye due to hypovitaminosis A following gut resection. Coincidental complications occur commonly in the general population and cannot be correlated to inflammatory bowel disease alone. These include conjunctivitis, recurrent corneal erosions, and corneal ulcer.11–13 Ocular involvement does not always coincide with active intestinal flare. However, in instances when it does, as is typical of episcleritis, this can be used as an indicator of disease activity, indicating the need for more aggressive management.12 In this case report, the pathogenesis of ischemia in retinal vasculitis is not clear but is suggested to be either thrombotic or obliterative, secondary to the infiltration of inflammatory cells. Based on histological studies, vascular changes in uveitis are characterized by perivascular infiltration of lymphocytes, which results in perivasculitis rather than true vasculitis of the vessel wall.14 Cell-mediated immunity also plays a role in the pathology of retinal vasculitis, with CD4+ T cells documented within and around the retinal vessels. Thrombotic vascular changes can occur due to local endothelial injury or increased prothrombin activity as observed in Behçet’s disease.14,15 The retina has a uniquely high metabolic demand for oxygen that is normally met by a highly efficient vascular supply. Insufficiency of the retinal circulation causes neuroretinal dysfunction and degeneration. Focal retinal ischemia results in selective damage to specific subpopulations of retinal neurons and can result in cellular death by apoptosis or necrosis, with dysfunction and degeneration of the inner retina and eventually visual loss. Retinal vascular obstruction can also promote the production of vascular endothelial growth factor, which increases vascular permeability and results in macular edema and induced neovascularization.15,16 Treatment of ocular manifestations ranges from controlling the underlying intestinal inflammation, topical steroids, systemic nonsteroidal anti-inflammatory drugs, systemic steroids, and immunosuppressant and biological agents. In refractory or severe cases, treatment with monoclonal antibodies has shown promise. Periodic examination by a retina specialist is recommended for patients being treated for CD.
  16 in total

1.  Histocompatibility antigens in inflammatory bowel disease. Their clinical significance and their association with arthropathy with special reference to HLA-B27 (W27).

Authors:  E G Mallas; P Mackintosh; P Asquith; W T Cooke
Journal:  Gut       Date:  1976-11       Impact factor: 23.059

Review 2.  The ocular manifestations of inflammatory bowel disease.

Authors:  Simon R J Taylor; Peter McCluskey; Susan Lightman
Journal:  Curr Opin Ophthalmol       Date:  2006-12       Impact factor: 3.761

3.  [Retinal vasculitis in Crohn's disease: a case report].

Authors:  S Trojet; H Mazlout; M Hamdouni; A Toumi; F Jebali; M Cheour; M A El Afrit; A Kraiem
Journal:  J Fr Ophtalmol       Date:  2009-12-21       Impact factor: 0.818

4.  Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients.

Authors:  Maddalena Zippi; Claudia Corrado; Roberta Pica; Eleonora Veronica Avallone; Claudio Cassieri; Daniela De Nitto; Paolo Paoluzi; Piero Vernia
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

5.  Spectrum and frequency of ophthalmologic manifestations in patients with inflammatory bowel disease: a prospective single-center study.

Authors:  Taxiarchis Felekis; Konstantinos Katsanos; Margarita Kitsanou; Nikolaos Trakos; Vasileios Theopistos; Dimitrios Christodoulou; Ioannis Asproudis; Epameinondas V Tsianos
Journal:  Inflamm Bowel Dis       Date:  2009-01       Impact factor: 5.325

6.  Primary, secondary and coincidental ocular complications of Crohn's disease.

Authors:  D L Knox; A P Schachat; E Mustonen
Journal:  Ophthalmology       Date:  1984-02       Impact factor: 12.079

7.  Visual outcome of patients with idiopathic ischaemic and non-ischaemic retinal vasculitis.

Authors:  H E Palmer; M R Stanford; M D Sanders; E M Graham
Journal:  Eye (Lond)       Date:  1996       Impact factor: 3.775

Review 8.  Crohn's disease.

Authors:  Rahul Kalla; Nicholas T Ventham; Jack Satsangi; Ian D R Arnott
Journal:  BMJ       Date:  2014-11-19

Review 9.  Ocular complications of inflammatory bowel disease.

Authors:  Rana Mady; Will Grover; Salim Butrus
Journal:  ScientificWorldJournal       Date:  2015-03-23

Review 10.  Ischemic retinal vasculitis and its management.

Authors:  Lazha Talat; Sue Lightman; Oren Tomkins-Netzer
Journal:  J Ophthalmol       Date:  2014-04-15       Impact factor: 1.909

View more
  2 in total

Review 1.  Ophthalmic manifestations in patients with inflammatory bowel disease: A review.

Authors:  Leandro Lopes Troncoso; Ana Luiza Biancardi; Haroldo Vieira de Moraes; Cyrla Zaltman
Journal:  World J Gastroenterol       Date:  2017-08-28       Impact factor: 5.742

Review 2.  Medical, ethical, and legal aspects of hematopoietic stem cell transplantation for Crohn's disease in Brazil.

Authors:  Milton Artur Ruiz; Roberto Luiz Kaiser Junior; Lilian Piron-Ruiz; Priscila Samara Saran; Lilian Castiglioni; Luiz Gustavo de Quadros; Tainara Souza Pinho; Richard K Burt
Journal:  World J Stem Cells       Date:  2020-10-26       Impact factor: 5.326

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.